Murray Epstein

Summary

Affiliation: University of Miami School of Medicine
Country: USA

Publications

  1. doi Statins in the management of dyslipidemia associated with chronic kidney disease
    Murray Epstein
    Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, 1201 North West 16th Street, Miami, FL 33125, USA
    Nat Rev Nephrol 8:214-23. 2012
  2. ncbi Lercanidipine: a novel dihydropyridine calcium-channel blocker
    M Epstein
    Division of Nephrology, University of Miami School of Medicine, Florida 33125, USA
    Heart Dis 3:398-407. 2001
  3. ncbi Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function
    Murray Epstein
    Department of Medicine, Division of Nephrology and Hypertension, University of Miami, Miami, FL, USA
    Am J Kidney Dis 45:2-14. 2005
  4. ncbi Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy
    Murray Epstein
    University of Miami School of Medicine, Miami, FL, USA
    Nat Clin Pract Nephrol 2:310-1. 2006
  5. ncbi Aldosterone blockade: an emerging strategy for abrogating progressive renal disease
    Murray Epstein
    Department of Medicine, University of Miami School of Medicine, Miami, Fla, USA
    Am J Med 119:912-9. 2006
  6. ncbi Resistant hypertension: prevalence and evolving concepts
    Murray Epstein
    Department of Medicine, University of Miami School of Medicine, Miami, FL, USA
    J Clin Hypertens (Greenwich) 9:2-6. 2007
  7. ncbi The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy
    Murray Epstein
    Professor of Medicine, Nephrology Section, VA Medical Center, Miami, FL 33125, USA
    Curr Hypertens Rep 9:98-105. 2007
  8. ncbi Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
    Murray Epstein
    University of Miami School of Medicine, Miami, Florida, USA
    Clin J Am Soc Nephrol 1:940-51. 2006
  9. doi Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics
    Murray Epstein
    Division of Nephrology and Hypertension, University of Miami, Miller School of Medicine, Miami, FL, USA
    J Clin Hypertens (Greenwich) 13:644-8. 2011
  10. ncbi Role of aldosterone blockade in the management of hypertension and cardiovascular disease
    Murray Epstein
    Department of Medicine, University of Miami School of Medicine, Miami, Fla, USA
    Contrib Nephrol 143:90-104. 2004

Detail Information

Publications27

  1. doi Statins in the management of dyslipidemia associated with chronic kidney disease
    Murray Epstein
    Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, 1201 North West 16th Street, Miami, FL 33125, USA
    Nat Rev Nephrol 8:214-23. 2012
    ..The potential adverse effects associated with statin therapy are important to consider in the management of dyslipidemia in patients with CKD...
  2. ncbi Lercanidipine: a novel dihydropyridine calcium-channel blocker
    M Epstein
    Division of Nephrology, University of Miami School of Medicine, Florida 33125, USA
    Heart Dis 3:398-407. 2001
    ....
  3. ncbi Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function
    Murray Epstein
    Department of Medicine, Division of Nephrology and Hypertension, University of Miami, Miami, FL, USA
    Am J Kidney Dis 45:2-14. 2005
    ..Other questions that remain to be addressed and issues that should be investigated also are presented...
  4. ncbi Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy
    Murray Epstein
    University of Miami School of Medicine, Miami, FL, USA
    Nat Clin Pract Nephrol 2:310-1. 2006
  5. ncbi Aldosterone blockade: an emerging strategy for abrogating progressive renal disease
    Murray Epstein
    Department of Medicine, University of Miami School of Medicine, Miami, Fla, USA
    Am J Med 119:912-9. 2006
    ....
  6. ncbi Resistant hypertension: prevalence and evolving concepts
    Murray Epstein
    Department of Medicine, University of Miami School of Medicine, Miami, FL, USA
    J Clin Hypertens (Greenwich) 9:2-6. 2007
    ..Consequently, aldosterone blockade constitutes an effective intervention for treating resistant hypertension...
  7. ncbi The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy
    Murray Epstein
    Professor of Medicine, Nephrology Section, VA Medical Center, Miami, FL 33125, USA
    Curr Hypertens Rep 9:98-105. 2007
    ..Consequently, aldosterone blockade constitutes an effective intervention for treating resistant hypertension...
  8. ncbi Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
    Murray Epstein
    University of Miami School of Medicine, Miami, Florida, USA
    Clin J Am Soc Nephrol 1:940-51. 2006
    ..Co-administration of EPL50 or EPL100 with an ACE inhibitor as compared with an ACE inhibitor alone significantly reduces albuminuria in patients with diabetes without producing significant increases in hyperkalemia...
  9. doi Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics
    Murray Epstein
    Division of Nephrology and Hypertension, University of Miami, Miller School of Medicine, Miami, FL, USA
    J Clin Hypertens (Greenwich) 13:644-8. 2011
    ....
  10. ncbi Role of aldosterone blockade in the management of hypertension and cardiovascular disease
    Murray Epstein
    Department of Medicine, University of Miami School of Medicine, Miami, Fla, USA
    Contrib Nephrol 143:90-104. 2004
  11. ncbi Recent landmark clinical trials: how do they modify the therapeutic paradigm?
    Murray Epstein
    Department of Medicine, University of Miami School of Medicine, Florida 33125, USA
    Am J Hypertens 15:82S-84S. 2002
    ..For example, in RENAAL, 78% of patients randomized to losartan required add-on therapy with a calcium antagonist. Calcium antagonists are an important and often necessary component of this multiple drug regimen...
  12. ncbi Evolving role of calcium antagonists in the management of hypertension
    Murray Epstein
    Department of Medicine, University of Miami School of Medicine, Miami, FL, USA
    Med Clin North Am 88:149-65. 2004
    ..Concomitantly, such formulations should promote increased patient compliance and thereby favorably influence hypertension-related morbidity and mortality...
  13. ncbi Aldosterone receptor blockade and the role of eplerenone: evolving perspectives
    Murray Epstein
    Nephrology Section, VA Medical Center, 1201 NW 16th Street, Miami, FL 33125, USA
    Nephrol Dial Transplant 18:1984-92. 2003
  14. ncbi Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus
    Richard A Preston
    Division of Clinical Pharmacology Research Center, Miami, Florida 33136, USA
    J Clin Pharmacol 42:754-61. 2002
    ..Whether there are differences between the drug classes in renal impairment remains to be determined...
  15. ncbi Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?
    Vito M Campese
    Division of Nephrology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Am Soc Nephrol 16:S11-7. 2005
    ..Also reviewed is the emerging database indicating that statins may modulate renal function by altering the response of the kidney to dyslipidemia...
  16. ncbi Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy
    Arif Asif
    Department of Medicine, Divison of Nephrology, University of Miami School of Medicine, 1600 NW 10th Avenue, Miami, FL 33136, USA
    J Clin Pharmacol 44:1342-51. 2004
    ..Additional studies are needed to properly evaluate the role of fenoldopam in radiocontrast-induced nephropathy prophylaxis...
  17. ncbi Atorvastatin does not induce glomerular or tubular dysfunction even at high doses
    Murray Epstein
    University of Miami School of Medicine, Miami, FL 33125, USA
    J Cardiometab Syndr 2:163-7. 2007
    ..These data indicate that in this patient population, atorvastatin, even at a high dose, does not interfere with renal tubular reabsorption of protein, induce renal tubular dysfunction, or alter glomerular filtration rate in humans...
  18. pmc Hypertension and chronic kidney disease progression: why the suboptimal outcomes?
    Anil K Bidani
    Department of Medicine, Loyola University Chicago, USA
    Am J Med 125:1057-62. 2012
    ..Meanwhile, more aggressive use of patient education and home blood pressure monitoring with selection of longer-acting antihypertensive agents or nocturnal dosing should be considered to improve the current suboptimal results...
  19. ncbi Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction
    Murray Epstein
    Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA
    J Hypertens Suppl 20:S17-23. 2002
    ..The pathogenesis is believed to be renal vasoconstriction secondary to inhibition of vasodilatory PGs with unopposed vasoconstrictor forces including angiotensin II, catecholamines and enhanced sympathetic activity...
  20. ncbi Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
    Janice G Douglas
    Case Western Reserve University, Department of Medicine, Room W 165, 10900 Euclid Ave, Cleveland, Ohio 44106, USA
    Arch Intern Med 163:525-41. 2003
  21. ncbi Prevention of radiocontrast-induced nephropathy
    Arif Asif
    Department of Medicine, Division of Nephrology, University of Miami School of Medicine, Miami, FL 33136, USA
    Am J Kidney Dis 44:12-24. 2004
    ..This review focuses on current interventions to ameliorate radiocontrast-induced acute renal failure and provides an analysis of some of the recent studies conducted to halt radiocontrast-induced nephropathy...
  22. ncbi Cyclooxygenase-2 expression and function in renal pathophysiology
    Radko Komers
    Division of Nephrology and Hypertension, Oregon Health Sciences University, Portland, Oregon, USA
    J Hypertens Suppl 20:S11-5. 2002
    ..Consequently, the pathophysiological states discussed herein include not only COX-2 induction during inflammation but also derangements in COX-2 expression and function caused by non-inflammatory stimuli...
  23. ncbi Relationship between erythropoietin administration and alterations of renin-angiotensin-aldosterone
    Reinaldo Rosario
    Division of Nephrology and Hypertension, Cleveland Clinic Florida, Weston, Florida, USA
    J Renin Angiotensin Aldosterone Syst 7:135-8. 2006
    ..The changes in ALDO levels after EPO administration in ESRD patients were discrepant with two studies reporting an increase, two reporting a decrease and the remaining three disclosing no change...
  24. ncbi Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Norman K Hollenberg
    Department of Radiology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Clin J Am Soc Nephrol 1:1046-8. 2006
  25. ncbi The use of calcium antagonists in the treatment of hypertensive persons with kidney disease
    Sheldon Tobe
    Division of Nephrology, Sunnybrook and Women s College HSC, A240 2075 Bayview Avenue, Toronto, Canada M4N 3M5
    Curr Hypertens Rep 4:191-4. 2002
    ....
  26. ncbi Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics
    Murray Epstein
    Am J Hypertens 17:638-9; author reply 639-40. 2004
  27. ncbi Aldosterone and large artery vessels
    Murray Epstein
    Hypertension 47:e24; author reply e25. 2006